Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma - 22/08/20
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
Abstract |
Introduction |
Pressurised metered dose inhalers (pMDIs) are effective drug delivery devices prescribed in obstructive airway diseases due to their convenience, portability, ease of enabling multiple doses in a single formulation, and storage in any orientation. For the management of asthma, the fixed-dose combination of a long-acting β2-agonist (LABA) and an inhaled corticosteroid (ICS) has been recommended by Global Initiative for Asthma guideline as a preferred treatment option for patients who are uncontrolled with only ICS doses. One of the available LABA/ICS combinations is the formoterol/budesonide (FB).
Areas covered |
This article systematically reviews the efficacy and safety of the FB pMDI compared with the FB dry powder inhaler (DPI), individual mono-components (formoterol and budesonide) or salmeterol/fluticasone (SF) combination in the treatment of asthma among paediatric and adult patients. PubMed was searched with the string: ‘‘((Budesonide) AND Formoterol) AND ((((pMDI) OR MDI) OR Pressurised Metered-dose inhaler) OR Metered-dose inhaler)’’, in ALL fields. Screening of all the articles was done till February 2020. We have included 24 articles from the total of 142 hits received.
Conclusions |
The FB pMDI is efficacious for the long-term management of asthma in patients 6 years of age and above. It has been shown to improve lung function and asthma control, and to reduce daytime and night-time symptoms, the number of rescue medication doses and asthma exacerbations. It also showed rapid onset of bronchodilatory effect with a dose–response relationship that allows patients to utilise it as a Single Maintenance And Reliever Therapy (SMART) regimen.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Formoterol/budesonide given via pMDI is an efficacious and well tolerated option for the long-term management of asthma. |
• | Formoterol/budesonide pMDI increases lung function and improves asthma control. |
• | It reduces day/night-time symptoms and asthma exacerbations. |
• | PMDI with a dose-counter potentially enhances patient compliance. |
• | Adding a non-static spacer with a valve to the FB pMDI may improve the drug deposition into the lungs. |
Keywords : Formoterol/budesonide, Asthma, Pressurised metered dose, Inhalers
Plan
Vol 170
Article 106055- août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?